Asia Deals Aim for First-in-Class Biology, with at Least Four Deals for New Targets

Why It Matters

The surge in first‑in‑class licensing positions Asian biotech as a critical source of breakthrough therapies, reshaping global pipeline strategies and investment flows.

Key Takeaways

• 72 deals announced in 2024‑25 involve Asian biotech sellers
• First‑in‑class assets out‑licensed exceed me‑better programs
• Four deals target novel proteins CNTN4, GPR52, MTARC1, OK‑1
• Global pharma partners seek discovery‑driven pipelines in Asia
• Shift indicates Asia moving from me‑too to innovation leadership

Pulse Analysis

The recent wave of 72 licensing agreements underscores a decisive pivot by Asian biotech firms toward first‑in‑class biology. Unlike traditional me‑too projects, these deals focus on uncharted targets such as CNTN4 and GPR52, reflecting a maturing R&D ecosystem that can generate differentiated assets. This shift is bolstered by robust government incentives and an expanding talent pool, enabling companies to pursue novel modalities ranging from gene‑editing to protein‑degradation platforms.

For multinational pharmaceutical giants, the Asian surge offers a strategic shortcut to fill pipeline gaps. As late‑stage attrition rates climb, firms like Boehringer Ingelheim and Eli Lilly are increasingly sourcing early‑stage, high‑risk assets from the region to diversify their discovery portfolios. The out‑licensing model reduces upfront capital exposure while granting access to cutting‑edge science, fostering collaborative frameworks that blend global development expertise with local innovation.

Looking ahead, the momentum is likely to accelerate as venture capital and sovereign wealth funds pour capital into Asian biotech hubs beyond China. Regulatory bodies are streamlining approval pathways, further incentivizing first‑in‑class pursuits. Consequently, the region is poised to evolve from a licensing source to a full‑cycle drug development powerhouse, reshaping competitive dynamics and setting new standards for global biotech collaboration.